The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay (NMD) inhibitor in patients with advanced/metastatic solid tumors (parts 1 and 2).
 
Shiraj Sen
Consulting or Advisory Role - Bayer; Guardant Health
Travel, Accommodations, Expenses - Bayer; Guardant Health
 
Benedito Carneiro
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Eisai
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Pyxis (Inst); Regeneron (Inst); Repare Therapeutics (Inst)
 
Judy Wang
Research Funding - Abbvie (Inst); Abdera Thereapeutics (Inst); Accent Therapeutics (Inst); Accutar Biotech (Inst); Acrivon Therapeutics (Inst); Adagene (Inst); Allorion Therapeutics (Inst); Alterome Therapeutics (Inst); Angiex (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); Axion Biosystems (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Circle Pharma (Inst); Compass Therapeutics (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Crescent (Inst); Cullinan Oncology (Inst); D3 Bio (Inst); DAAN Biotherapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Day One Biopharmaceuticals (Inst); DualityBio (Inst); Edgewood Oncology (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Genentech (Inst); Genmab (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); Halda Therapeutics (Inst); Hotspot Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kumquat (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo/Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MBQ Pharma (Inst); MediLink Therapeutics (Inst); Menarini (Inst); Merck KGaA (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Pyxis (Inst); Quanta Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Syndax (Inst); Systimmune (Inst); Tango Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zai Lab (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; NGM Biopharmaceuticals
 
Shigehiro Koganemaru
Research Funding - Abbvie (Inst); Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi-Sankyo (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Kyowa Kirin International; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Kyowa Kirin; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kyowa Kirin (Inst); Lilly (Inst); Loxo/Lilly (Inst); Medpace (Inst); Merck KGaA (Inst); Moderna Therapeutics (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst); Takara Bio (Inst); Takeda (Inst)
 
Naoto Yoshizuka
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Shota Mizuno
Employment - Daiichisankyo
 
Abdul Waheed Rajper
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Ang Li
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Anthony Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Immunome; Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Affinia Therapeutics (Inst); Agenus (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Coretag Therapeutics (Inst); Cullinan Oncology (Inst); Curadev Pharma, Inc. (Inst); Daiichi Sankyo, Inc. (Inst); Day One Biopharmaceuticals, Inc., (Inst); Deka Biosciences (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Exelixis (Inst); FibroGen (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HEXAGON BIO, INC. (Inst); HiberCell (Inst); Horizon CME (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); Immuto Scientific (Inst); IMPAC Medical Systems (Inst); Indupro Inc (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Kivu Bioscience (Inst); Leerink (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Medicxi (Inst); Mekanistic Therapeutics (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Merck KGaA (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics, Inc (Cytel) (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Nested Therapeutics (Inst); Novo Nordisk (Inst); Novo Ventures (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Pierre Fabre (Inst); Praxia Precision Medicines (Inst); Praxis Precision Medicines (Inst); Prelude Therapeutics (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); Singzyme Pte Ltd (Inst); Singzyme Pte Ltd (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Spirea Limited Inc. (Inst); Stratus Therapeutics Inc (Inst); Sun Pharma Advanced Research Company (Inst); Tagworks Pharmaceuticals (Inst); Tensegrity Pharma, Inc (Inst); TheraTechnologies (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Tubulis GmbH (Inst); Venus Oncology (Inst); Verastem (Inst); VIDA VENTURES ADVISORS, LLC (Inst); Vincerx Pharma (Inst); Vincerx Pharma (Inst); Voyant Bio (Ask Mendel AI Inc) (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Patents, Royalties, Other Intellectual Property - Ascentage Pharma; Zentails
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)